10-QPeriod: Q1 FY2014

AbbVie Inc. Quarterly Report for Q1 Ended Mar 31, 2014

Filed May 9, 2014For Securities:ABBV

Summary

AbbVie Inc. reported solid financial results for the first quarter of 2014, demonstrating year-over-year growth in key areas. Net sales increased by 5% to $4.56 billion, driven primarily by the sustained strength of its flagship product, HUMIRA, which saw an 18% increase in global sales. This growth was further bolstered by double-digit sales increases from products like Synthroid, Creon, and Duodopa. Despite facing headwinds from the loss of exclusivity in its lipid franchise, which resulted in a significant revenue decline, AbbVie managed to maintain profitability, reporting diluted earnings per share of $0.61, consistent with the prior year. The company also continued to invest significantly in its research and development pipeline, with R&D expenses rising by 22% to $772 million, underscoring its commitment to future growth through innovation. AbbVie's strong operational performance and strategic R&D investments position it well for continued success.

Financial Highlights

49 data points
Beta

Revenue

$4.56B

75.9% Gross Margin

Net Income

$980.00M

21.5% Net Margin

EPS (Diluted)

$0.61

Total Assets

$28.66B

Cash & Equivalents

$8.14B

Free Cash Flow

$487.00M

Financial Statements
Beta
Revenue$4.56B
Cost of Revenue$1.10B
Gross Profit$3.46B
SG&A Expenses$1.34B
Operating Expenses$3.21B
Operating Income$1.35B
Interest Expense$70.00M
Net Income$980.00M
EPS (Basic)$0.61
EPS (Diluted)$0.61
Shares Outstanding (Basic)1.59B
Shares Outstanding (Diluted)1.61B

Key Highlights

  • 1Net sales grew 5% to $4.56 billion in Q1 2014.
  • 2HUMIRA sales increased 18% globally to $2.64 billion, driven by continued strength across therapeutic categories and geographies.
  • 3R&D expenses increased 22% to $772 million, reflecting investment in pipeline development and new indications for existing products.
  • 4Diluted earnings per share remained stable at $0.61 compared to Q1 2013.
  • 5Gross profit margin improved to 76% from 73% in the prior year, aided by product mix and operational efficiencies.
  • 6AbbVie repurchased approximately $250 million of its stock during the quarter under its $1.5 billion share repurchase program.

Frequently Asked Questions

AbbVie reported a 5% increase in worldwide net sales, reaching $4.56 billion for the first quarter of 2014. This growth was primarily attributed to the strong performance of HUMIRA and other key products such as Synthroid, Creon, and Duodopa, which helped offset the decline in its lipid franchise due to loss of exclusivity.

HUMIRA remains AbbVie's largest product, with global sales increasing by 18% to $2.64 billion in Q1 2014. The growth is driven by continued market expansion across various therapeutic categories and geographies, higher market share, and favorable pricing in certain regions. AbbVie is also actively pursuing new indications for HUMIRA to ensure its sustained growth.

AbbVie is significantly investing in its future through research and development. R&D expenses rose by 22% to $772 million in Q1 2014, reflecting increased funding for late-stage pipeline assets and additional HUMIRA indications. This investment is crucial for its long-term strategy of developing innovative therapies.

AbbVie demonstrated a commitment to returning capital to shareholders. During Q1 2014, the company repurchased approximately $250 million of its stock under its $1.5 billion repurchase program. Additionally, the company declared a quarterly cash dividend of $0.42 per share, representing a 5% increase from the previous quarter, indicating confidence in its financial stability and future prospects.